On the wire:
“Surgical teams are actively seeking innovative wound-closure products with improved performance and ease-of-use to seal surgical staple lines and stop severe bleeding,” one of the inventors, Ishay Attar, told ISRAEL21c.
Living in Haifa during the 2006 Israel–Hezbollah war, Attar and fellow biomedical engineer Orahn Preiss-Bloom were horrified by television images of bleeding victims. It seemed to them that existing methods for “sealing” injuries were inadequate to cope with complex shrapnel wounds.
Market research confirmed this and one year later, he and Preiss-Bloom launched LifeBond, an innovative sealant made of biocompatible substances that can close wounds.
The report from ISRAEL21c describes the technology: The sealant incorporates an adhesive formulation that mimics late stage blood coagulation. It forms a network similar to the fibrin network of blood clots, but has demonstrated adhesive strength even greater than that of blood-derived fibrin sealants.
In US and Israeli clinical trials, the product has shown great promise in preventing life-threatening leakage from surgical connections between blood vessels and organs, reports Attar.
“We will apply for regulatory approval in the United States, Europe, and Israel next year, and we anticipate that our initial sealant will reach the market in two to three years.”
LifeBond, which is supported by $10 million in financing from GlenRock Israel, the Zitelman Group, Pitango, and Robert Taub, founder and former CEO of Omrix Biopharmaceuticals (recently acquired by Johnson & Johnson), is also developing LifePatch, a bleeding-control product based on the same platform technology.
To read the full story click hereAnnie Ellerton